Literature DB >> 19344467

Outcome after liver transplantation for NASH cirrhosis.

S M Malik1, M E deVera, P Fontes, O Shaikh, J Ahmad.   

Abstract

Nonalcoholic steatohepatitis (NASH) associated cirrhosis is an increasing indication for liver transplant (LT). The aim of this study was to determine outcome and poor predictive factors after LT for NASH cirrhosis. We analyzed patients undergoing LT from 1997 to 2008 at a single center. NASH was diagnosed on histopathology. LT recipients with hepatitis C, alcoholic or cholestatic liver disease and cryptogenic cirrhosis acted as matched controls. Ninety-eight LT recipients were identified with NASH cirrhosis. Compared to controls, NASH patients had a higher BMI (mean 32.3 kg/m2), and were more likely to be diabetic and hypertensive. Mortality after transplant was similar between NASH patients and controls but there was a tendency for higher earlier mortality in NASH patients (30-day mortality 6.1%, 1-year mortality 21.4%). Sepsis accounted for half of all deaths in NASH patients, significantly higher than controls. NASH patients > or =60 years, BMI > or =30 kg/m2 with diabetes and hypertension (HTN) had a 50% 1-year mortality. In conclusion, patients undergoing LT for NASH cirrhosis have a similar outcome to patients undergoing LT for other indications. The combination of older age, higher BMI, diabetes and HTN are associated with poor outcome after LT. Careful consideration is warranted before offering LT to these high-risk patients.

Entities:  

Mesh:

Year:  2009        PMID: 19344467     DOI: 10.1111/j.1600-6143.2009.02590.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  47 in total

Review 1.  Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.

Authors:  Adnan Said
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Incidence of Recurrent NASH-Related Allograft Cirrhosis.

Authors:  Shelly Kakar; Mohannad Dugum; Ricardo Cabello; Abhinav Humar; Jawad Ahmad; Shahid M Malik
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

Review 3.  Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.

Authors:  Amit D Tevar; Calissia Clarke; Jiang Wang; Steven M Rudich; E Steve Woodle; Alex B Lentsch; Michael L Edwards
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

Review 4.  Liver transplantation and nonalcoholic fatty liver disease.

Authors:  Kymberly D Watt
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

5.  Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Lisa B VanWagner; Brittany Lapin; Anton I Skaro; Donald M Lloyd-Jones; Mary E Rinella
Journal:  Liver Int       Date:  2015-06-03       Impact factor: 5.828

Review 6.  Perioperative nutritional therapy in liver transplantation.

Authors:  Ahmed Hammad; Toshimi Kaido; Shinji Uemoto
Journal:  Surg Today       Date:  2014-01-29       Impact factor: 2.549

Review 7.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

Review 8.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

9.  Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.

Authors:  Jacqueline G O'Leary; Carmen Landaverde; Linda Jennings; Robert M Goldstein; Gary L Davis
Journal:  Clin Gastroenterol Hepatol       Date:  2011-04-15       Impact factor: 11.382

10.  Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases.

Authors:  Christopher Kennedy; David Redden; Stephen Gray; Devin Eckhoff; Omar Massoud; Brendan McGuire; Basem Alkurdi; Joseph Bloomer; Derek A DuBay
Journal:  HPB (Oxford)       Date:  2012-06-14       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.